Researchers at The University of Texas MD Anderson Cancer Center report an immune pathway that may help oral precancerous lesions progress to head and neck squamous cell carcinoma. The work focuses on early changes in the tumor microenvironment—shifts that can quietly establish immune tolerance long before invasive cancer appears.
Published in Cancer Research, the study was led by Yu Leo Lei, D.D.S., Ph.D., with co–first authors Wang Gong, Ph.D., and Hülya Taner, D.D.S., Ph.D. It combines preclinical models with observations from human lesions that later developed cancer, linking immune dysregulation to clinical risk.
A key finding is the emergence of suppressive myeloid cells in a subset of lesions. These cells show elevated activity in pathways tied to inflammation and chemotaxis, including high SOX2-associated programs and increased expression signatures involving SLC2A1 and SPP1, while interferon signaling remains weak—an imbalance that undermines normal immune defense.
Mechanistically, cells with high SOX2 expression release CCL2, an inflammatory signal that recruits myeloid cells. Once recruited, the cells adopt an immunosuppressive state characterized by increased IL-1α, SLC2A1, and SPP1, together with reduced type-I interferon target genes that typically support antitumor activity.
The authors further show that IL-1α can dampen STING pathway activity, weakening how the immune system recognizes abnormal cells. This creates a feedback environment in which suppressive cells can persist and immune surveillance fails.
Importantly, pharmacologic interruption of the IL-1α receptor reduced the fraction of immunosuppressive myeloid cells, delayed tumor development, and improved survival in preclinical experiments. The data suggest that interrupting this signaling axis could be explored as a prevention strategy rather than a treatment after invasion.
Beyond therapy, the study proposes candidate biomarkers for identifying high-risk precancerous lesions. Current WHO histology grading does not reliably predict progression, leaving clinicians with limited tools to target early intervention to those most likely to develop cancer.
Taken together, the findings point to IL-1α as both a driver of immune tolerance and a tractable target for immunoprevention. The group also notes ongoing and planned efforts to validate biomarker performance in larger human cohorts and to test IL-1α pathway inhibition in preventive clinical trial settings.
